| COVID-19 Clinical Research Studies | Lifetime | 154 | KR 4 | 99.16 |
| Long-Term Effects of COVID-19 | Lifetime | 140 | KR 1 | 98.52 |
| Vasculitis and related conditions | Lifetime | 79 | KR 1 | 98.89 |
| Renal Diseases and Glomerulopathies | Lifetime | 156 | KR 1 | 98.98 |
| Vascular anomalies and interventions | Lifetime | 86 | KR 1 | 98.58 |
| COVID-19 and Mental Health | Lifetime | 576 | KR 8 | 96.08 |
| Nephrotoxicity and Medicinal Plants | Lifetime | 56 | KR 2 | 94.85 |
| Renal and Vascular Pathologies | Lifetime | 894 | KR 10 | 95.47 |
| COVID-19 Impact on Reproduction | Lifetime | 915 | KR 6 | 86.39 |
| COVID-19 Clinical Research Studies | 2021-2025 | 220 | KR 3 | 98.85 |
| Long-Term Effects of COVID-19 | 2021-2025 | 155 | KR 3 | 98.12 |
| Chronic Disease Management Strategies | 2021-2025 | 53 | KR 2 | 97.61 |
| Health disparities and outcomes | 2021-2025 | 125 | KR 2 | 97.26 |
| COVID-19 and Mental Health | 2021-2025 | 425 | KR 9 | 96.15 |
| Health Systems, Economic Evaluations, Quality of Life | 2021-2025 | 405 | KR 3 | 96.22 |
| Child Nutrition and Feeding Issues | 2021-2025 | 163 | KR 1 | 93.60 |
| Nutrition and Health in Aging | 2021-2025 | 675 | KR 32 | 93.34 |
| Food Security and Health in Diverse Populations | 2021-2025 | 349 | KR 4 | 91.16 |
| Renal Diseases and Glomerulopathies | 2021-2025 | 626 | KR 11 | 89.35 |
| Suicide and Self-Harm Studies | 2021-2025 | 620 | KR 13 | 87.60 |
| Heparin-Induced Thrombocytopenia and Thrombosis | 2021-2025 | 174 | KR 8 | 84.07 |
| Physical Activity and Health | 2021-2025 | 764 | KR 12 | 87.21 |
| Mental Health Treatment and Access | 2021-2025 | 836 | KR 4 | 86.48 |
| Vasculitis and related conditions | 2021-2025 | 504 | KR 10 | 85.27 |
| Global Public Health Policies and Epidemiology | 2021-2025 | 727 | KR 4 | 78.82 |
| Protein Tyrosine Phosphatases | 2021-2025 | 245 | KR 6 | 69.72 |
| Poxvirus research and outbreaks | 2021-2025 | 811 | KR 4 | 67.47 |
| Meta-analysis and systematic reviews | 2021-2025 | 970 | KR 6 | 68.21 |
| Mental Health and Psychiatry | 2021-2025 | 938 | KR 2 | 65.75 |
| Pharmacovigilance and Adverse Drug Reactions | 2021-2025 | 744 | KR 30 | 55.53 |
| Vascular anomalies and interventions | 2021-2025 | 936 | KR 12 | 49.92 |
| Animal testing and alternatives | 2021-2025 | 988 | KR 24 | 35.71 |
